Maria Thompson

By some estimates, the pharmaceutical outsourcing market could grow to $65 billion by 2018, fueled by a compound annual growth rate of nearly 15...

I’m sure it comes as no surprise to anyone reading this article that we have a problem in drug development. Pharmaceutical companies are having to...

Rare diseases by definition only affect a small number of people, but rare disease studies can reveal valuable information for more common...

Recently, Oxbridge Biotech Roundtable (OBR) interviewed Scientist’s Kevin Lustig about how his career decisions and approach to research shaped his...

Last month we ran a series of blog posts about next generation sequencing. Among the topics discussed were the limitations of next generation...

We’ve covered many different aspects of pharmaceutical innovation, ranging from organizational structure, patents, and incubators, but are there...

Here at Scientist, for the past few weeks we’ve been running a series of blog posts about stem cells discussing why iPS make an attractive research...

In the field of synthetic chemistry, the “elephant in the room” is that chemists spend most of their time just trying to reproduce published...

In our previous post on stem cells, we discussed how human-derived induced pluripotent stem cells (iPS) are being used to model “disease in a...

Carlsbad, CA is soon to be home to San Diego’s own community laboratory space. Much along the lines of Genspace in NYC and BioCurious in Sunnyvale...